Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and Terfenadine

[1]  H. Villar,et al.  Strategies for Indirect Computer-Aided Drug Design , 1993, Pharmaceutical Research.

[2]  J. Palacios,et al.  The role of ketoconazole in the QTc interval prolonging effects of H1‐antihistamines in a guinea‐pig model of arrhythmogenicity , 1996, British journal of pharmacology.

[3]  J. Llenas,et al.  Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig. , 1996, Arzneimittel-Forschung.

[4]  T. Bolton,et al.  Two types of ATP‐sensitive potassium channels in rat portal vein smooth muscle cells , 1996, British journal of pharmacology.

[5]  L. Wiseman,et al.  Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. , 1996, Drugs.

[6]  R. Egan,et al.  Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.

[7]  R. Egan,et al.  Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. , 1996, Arzneimittel-Forschung.

[8]  C. Picado,et al.  A Review of its Pharmacological Properties and Clinical Efficacy in the Treatment of Allergic Disorders , 1996 .

[9]  T. Ito,et al.  Effects of histamine H1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. , 1996, Archives internationales de pharmacodynamie et de therapie.

[10]  J. Venhorst,et al.  The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. , 1995, Journal of medicinal chemistry.

[11]  D. Roden,et al.  Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers , 1995, British journal of pharmacology.

[12]  W. Crumb,et al.  Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. , 1995, Molecular pharmacology.

[13]  Bernard Testa,et al.  Lipophilicity and hydrogen-bonding capacity of H1-antihistaminic agents in relation to their central sedative side-effects , 1994 .

[14]  Peter S. Shenkin,et al.  Cluster analysis of molecular conformations , 1994, J. Comput. Chem..

[15]  H. Villar,et al.  Molecular electrostatic potential of D1 and D2 dopamine agonists. , 1994, Journal of medicinal chemistry.

[16]  Molecular model of the interaction of bee venom phospholipase A2 with manoalide. , 1993, Journal of medicinal chemistry.

[17]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[18]  R C Wade,et al.  Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. , 1993, Journal of medicinal chemistry.

[19]  R L Somorjai,et al.  Fuzzy cluster analysis of molecular dynamics trajectories , 1992, Proteins.

[20]  H. Timmerman,et al.  QSAR and Molecular Modelling Studies on Histamine H1‐Receptor Antagonists , 1992 .

[21]  Henk Timmerman,et al.  The histamine H1-receptor antagonist binding site. Part I: Active conformation of cyproheptadine , 1991, J. Comput. Aided Mol. Des..

[22]  P. Carrupt,et al.  Molecular electrostatic potentials for characterizing drug-biosystem interactions. , 1991, Methods in enzymology.

[23]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[24]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[25]  R. Wade,et al.  New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. , 1989, Journal of medicinal chemistry.

[26]  N. W. Murrall,et al.  How accurate does a force field need to be? , 1989, Comput. Chem..

[27]  Drug design: Le contrôle LUMO du pharmacophore neuroleptique , 1987 .

[28]  H. Weinstein,et al.  A finite expansion method for the calculation and interpretation of molecular electrostatic potentials , 1986 .

[29]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[30]  R. Heel,et al.  Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. , 1985, Drugs.

[31]  C. Giessner-Prettre,et al.  Molecular electrostatic potentials: Comparison of ab initio and CNDO results , 1972 .

[32]  T. Edition,et al.  The determination of ionization constants , 1971 .